The arrogance of success is to think that what you did yesterday will be sufficient for tomorrow -William Pollard
On Friday, we wrapped a whirlwind week of all things performance at The 2018 OPEN MINDS Performance Management. My takeaways were many, but there were a few key themes: The focus on value (and performance) will continue. The measures of “great performance” are changing. And, organizations that can’t adopt emerging technologies—for analytics, decision support, treatment, and more—won’t be able to make the grade on the cost or consumer benefit side of the equation.
The health and human service field does not have a great track record for rapid innovation adoption, and the use of “cutting edge” treatment technology isn’t exactly a hallmark of the field. This was made painfully obvious to me when we recently reported on the state of evidence-based medicine for consumers with a serious mental illness—Why Do Only A Third Of Consumers With SMI Receive Evidence-Based Treatment?.
But health and human service organizations may not have the luxury of lagging on the adoption front for new treatment tools. There is too much competition for consumers, anxious for new treatment solutions. And there is competition for payer contracts who are interested in better value. In my recent article on the changing market definition of value—What’s The Window To Value-Based Care?—consistent clinical excellence and cutting-edge clinical expertise are integral parts of that emerging value equation. And new scientific discoveries that affect the treatment of chronic conditions are being made at a rapid clip—and being brought to market at a rapid rate.
There is a proliferation of online cognitive behavioral health therapy and the emergence of on-demand direct to consumer telehealth services (see How Technology Is Changing Case Management, The On-Demand, Direct-To-Consumer Online Therapy Market – A Glimpse, The Future Of Health Care Technology: A Town Hall Discussion With Digital Health Executives, and Another Disruptor To Business As Usual – Peer Support) And, in just the past year, we’ve seen FDA approval a number of potentially “game changing” treatment innovations:
- FDA Approves Pear Therapeutic reSET Prescription Mobile CBT App For Outpatient Addiction Treatment
- FDA Approves First Device To Treat Opioid Withdrawal Symptoms
- FDA Approves Sublocade, A Once-Monthly Buprenorphine Injection
- FDA Approves Six-Month Implant For Opioid Addiction Treatment
- FDA Approves Abilify MyCite® (Aripiprazole Tablets With Sensor), A Pill With Digital Sensor To Track Oral Antipsychotic Ingestion
- WellDoc receives FDA clearance for non-prescription version of diabetes management app
And there is more on the way. There are 245 medications in the current FDA approval pipeline that should result in a number of new medications coming to market in the next few years (for more on that, check out our market intelligence report: The FDA Pipeline For Medications For Behavioral & Cognitive Conditions: A 2018 OPEN MINDS Update).
Is your clinical team ready to compete on consistently excellent, cutting edge clinical services? Does your team have a structured process for evaluating new technologies and treatments as they come to market? Does your team create and launch new services lines in a structured and efficient way? If you want to learn more about the best practices in evolving consumer service and clinical treatment models, check out these resources in our OPEN MINDS Industry Library:
- Everything An Executive Needs To Build A Successful Tech Strategy: An Exclusive CEO Roundtable Discussion
- Diversifying Your Revenue Streams: How To Successfully Launch A New Service Line
- Planning For The Digital Reinvention Of Your Market
- The Emerging Digital Treatment Era
- Leading The Newly Merged Tech-Enabled Organization
- Leveraging Technology For Strategic Advantage: Why Technology Will Be The Key To Future Competitive Advantage
- Building A Technology Infrastructure For Value-Based Care: Tech To Optimize The Value Of Consumer Care
If you want to learn more, join us at our first summit focused on clinical innovation—“Designing & Implementing Innovative Treatment Programs: An OPEN MINDS Executive Summit & Showcase”, at The 2018 OPEN MINDS Management Best Practices Institute on August 14 in Long Beach, California. The summit, which will be chaired by my colleague Annie Medina, will provide a forum for executives to learn about the trends in treatment innovations shaping the health and human services and hear case studies from organizations that have implemented cutting-edge new clinical programs, fueled by new treatment models and technologies.
Better yet, if your organization has built a cutting-edge clinical program based on new treatment technology, present your case study at our summit. Fill out an application on your program in order to participate in the summit. Applications are due by March 15, and case studies will be selected in April 2018. (If you have questions about the summit or the application process, contact Stacey Cotton, Institute Director at 877-350-6463 or email@example.com.)